Acepodia is doubling down on its cancer cell therapy development with a $109 million series C round. The funding comes after a $47 million B round in March and multiple C-suite hires since then.…
Apparently not content to work toward improving cancer care from just one angle, Johnson & Johnson’s Janssen R&D unit and molecular data gatherer Tempus have expanded their partnership.
Nearly two years after the Trump administration tasked private health insurers with reimbursing the total costs of point-of-care COVID tests and health services, Biden will expand that requirement to…
More dollars are flowing into the epigenome, with multiple VC shops backing new biotech Tune Therapeutics with $40 million to dial up or turn down gene expression. The North Carolina and Seattle-based…
Venclose’s solution uses a radiofrequency ablation catheter threaded into the compromised vein to deliver heat and shrink the vessel. Once complete, the blood will naturally reroute its flow to nearby…
Major U.K. Big Pharma GlaxoSmithKline and leading academic center the University of Oxford have penned a five-year research deal focused on making smarter bets on so-called ‘digital biology.’
The SEC charged former Immunomedics Chief Financial Officer Usama Malik with insider trading during his time at the biopharma, now owned by Gilead. As a result, Malik was fired as CEO and director of…
Through thoughtful consumer-centric design and application, these digital fertility solutions have the potential to smooth the path towards parenthood for countless couples and individuals around the…
Ivermectin and other unauthorized covid treatments have become a major source of dispute in recent months. Lawsuits over hospitals’ refusals to provide ivermectin to patients have been filed in Texas,…
Novartis is betting $150 million on a rival to Parkinson’s disease drugs in development at companies including Roche and AstraZeneca. The deal sees Novartis commit to pay UCB up to around $1.5 billion…
